BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results
Summary
TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its first quarter of fiscal year 2021, ended June 30, 2020. It is truly unprecedented, which is why BIONIK is operating under a modified plan to reduce costs and otherwise address the effects on our business caused by COVID-19. The single platform, already deployed in one Kindred site, that can be accessed anywhere, anytime, helps increasing technology adoption due to convenience and ease-of-use for the clinician, hospital management and headquarter teams.” BIONIK continues to expect to achieve the following milestones during fiscal year 2021: Sales for the quarter ended June 30, 2020 were $257,908, compared with $790,379 for the quarter ended June 30, 20119. In addition, deferred revenue, comprised of training to be provided and extended warranties, decreased to $582,281 at June 30, 2020 from $616,063 at March 31, 2020. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of robotic rehabilitation products and other Company products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Companys future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above.